Comparing ARIA‐E severity scales and effects of treatment management thresholds
Gregory Klein(Roche (Switzerland)), Rachelle S. Doody(Baylor College of Medicine), Monika Baudler(Roche (Switzerland)), Marco Lyons(Roche (United Kingdom)), Paul Delmar(Roche (Switzerland)), Derk D. Purcell(BioClinica (United States)), Paulo Fontoura(Roche (Switzerland)), Luc Bracoud(BioClinica (United States)), Jakub Wojtowicz(Roche (Switzerland)), Frederik Barkhof(National Hospital for Neurology and Neurosurgery), Jerome Barakos(Sutter Health), Jochen B. Fiebach(Pathodiagnostik Berlin), Szofia Bullain(Roche (Switzerland)), Marzia A. Scelsi(Roche (United Kingdom))
Cited by 2
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k